|
|
|
|
|
|
|
|
|
|
Detailed Programme
Detailed Programme 2016
- Saturday / Sunday, May 15, 2016
- Monday, May 16, 2016
- Tuesday, May 17, 2016
Book of Abstracts (.pdf)
Saturday, May 14, 2016 |
||
| 08:00 - 17:30 | Registration Open | |
| 18:00 - 21:00 | Opening Reception in MYST Lounge (Hilton Fallsview) | |
Sunday, May 15, 2016 |
||
| 07:30 - 08:30 | Continental Breakfast in Ballroom Foyer | |
| 07:30 - 08:30 | Poster Set-up for all Poster Presenters | |
| 08:00 - 18:00 | Registration Open | |
| 08:30 - 10:45 | Symposium I - Genetics & Genome Dynamics: Beyond TCGA Moderators: Patricia Tonin, PhD, McGill University, Montreal, QC, Canada Mark Carey, MD, University of British Columbia, Vancouver, BC, Canada |
|
| 08:30 | Welcome Remarks |
SY-01.00
|
| Trevor Shepherd, PhD, The University of Western Ontario, London, ON, Canada Elisabeth Baugh, CEO, Ovarian Cancer Canada, Toronto, ON, Canada |
||
| 08:45 | Determinants of resistance and response in high grade serous ovarian cancer |
SY-01.01
|
| David Bowtell Peter MacCallum Cancer Centre, Melbourne, Australia |
||
| 09:45 | Toward precision medicine for rare and common ovarian cancers |
SY-01.02
|
| Douglas Levine Memorial Sloan Kettering Cancer Center, New York, NY, United States |
||
| 10:15 - 10:30 | Health Break in Ballroom Foyer | |
| 10:30 - 12:00 | Symposium I (cont.) - Origins of Ovarian Cancer: From Basic Insights to New Screening Strategies | |
| 10:30 | Clonal evolution in high grade serous ovarian cancer: implications for intraperitoneal spread |
SY-01.03
|
| Sohrab Shah University of British Columbia, Vancouver, BC, Canada |
||
| 11:00 | Probing the genetic architecture of the response to PARP inhibitors |
SY-01.04
|
| Daniel Durocher The Senior Investigator & Assistant Director for Biomedical Research The Lunenfeld-Tanenbaum Research, Toronto, ON, Canada |
||
| 11:30 | Genomic Analysis of Mucinous Tumors (GAMuT): an international study to characterize this rare ovarian subtype |
SY-01.05
|
| Kylie Gorringe1; Dane Cheasley1; Matthew Wakefield2; Andrew Stephens3; Scott Kaufmann4; Charlie Gourley5; David Bowtell6; Yoland Antill7; Jessica McAlpine8; Clare Scott9; Ian Campbell1 1Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; 2Walter and Eliza Hall Institute and The University of Melbourne, Parkville, VIC, Australia; 3MIMR-PHI Institute of Medical Research, Clayton, VIC, Australia; 4Mayo Clinic, Rochester, MN, United States; 5University of Edinburgh, Edinburgh, Lothian, United Kingdom; 6Peter MacCallum Cancer Centre, Australian Ovarian Cancer Study and CASCADE, East Melbourne, VIC, Australia; 7Royal Melbourne Hospital and Monash University, Melbourne, VIC, Australia; 8BC Cancer Agency and OVCARE Tissue Bank, Vancouver, BC, Canada; 9Walter and Eliza Hall Institute, Royal Melbourne and Royal Women’s Hospitals, Parkville, VIC, Australia |
||
| 11:45 | Genomic consequences of aberrant DNA repair stratify ovarian cancer histotypes |
SY-01.06
|
| Yikan Wang1; Ali Bashashati1; Michael Anglesio2; Dawn Cochrane1; Diljot Grewal2; Hugo Horlings1; Anthony Karnezis1; Anne-Marie Mes-Mason3; Aikou Okamoto4; Satoshi Yanagida4; Nozomu Yanaihara4; Misato Saito4; Blake Gilks2; Jessica McAlpine2; Samuel Aparicio1; David Huntsman2; Sohrab Shah2 1BC Cancer Agency, Vancouver, BC, Canada; 2University of British Columbia, Vancouver, BC, Canada; 3University of Montreal, Montreal, QC, Canada; 4The Jikei University School of Medicine, Minato, Tokyo, Japan |
||
| 12:00 - 13:00 | Lunch Break in Watermark (Dessert and coffee will be served at the poster session) | |
| 13:00 - 14:30 | Poster Session I - Genetics, Genomics, Proteomics, Biomarkers, Pathology, Epidemiology & Prevention, Cell Culture and Animal Model Systems | |
| Characterization of small nucleolar ARNS (snoRNAs) in low malignant potential and high grade serous ovarian cancer tissues by transcriptomics |
P-01
|
|
| Audrey Roy1; Fabien Dupuis-Sandoval1; Sonia Couture2; Ryan Nottingham3; Alan Lambowitz3; Sherif Abou-Elela2; Michelle Scott1 1Department of Biochemistry, Université de Sherbrooke, Sherbrooke, QC, Canada; 2Department of Microbiology, Université de Sherbrooke, Sherbrooke, QC, Canada; 3Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX, United States |
||
| Elucidating the role of GALNT3 mediated aberrant mucin O-glycosylation in the progression of epithelial ovarian cancer |
P-03
|
|
| Razan Sheta1,2Christina M. Woo3, Florence Roux-Dalvai4, Frédéric Fournier4, Sylvie Bourassa4, Arnaud Droit1,4, Carolyn R. Bertozzi3,5 and Dimcho Bachvarov1,2 1Department of Molecular Medicine, Laval University, Québec PQ, Canada 2Centre de recherche du CHU de Québec, L’Hôtel-Dieu de Québec, Québec PQ, Canada 3Department of Chemistry, Stanford University, Stanford, CA, USA 4Centre de recherche du CHU de Québec, CHUL, Québec PQ, Canada 5Howard Hughes Medical Institute, Stanford University, Stanford, CA USA |
||
| GREB1 is frequently expressed in the female reproductive tract and all ovarian cancer histotypes and promotes proliferation in ovarian cancer cell lines and mouse models |
P-05
|
|
| Kendra Hodgkinson1; Bojana Djordjevic2; Kenneth Garson3; Barbara Vanderhyden1 1Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, Canada; 2Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada; 3Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada |
||
| A targeted next generation sequencing assay to characterize relevant cancer variants in solid tumor samples |
P-07
|
|
| Nick Khazanov Thermo Fisher Scientific, Ann Arbor, MI, United States |
||
| The Prevent Ovarian Cancer Program (POCP): a new model for the identification and care of women at risk for ovarian cancer |
P-11
|
|
| Alicia Tone1; Jeanna McCuaig1; Carl Virtanen1; Sarah Ferguson1; Raymond Kim1; Gary Rodin1; Patricia Shaw2; Amit Oza1; Suzanne Kamel-Reid1; Tracy Stockley1; Marcus Bernardini1 1Princess Margaret Cancer Centre, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada |
||
| Differential gene expression in fallopian tube epithelial cells associated with BRCA1 or BRCA2 mutation status and periovulatory follicular fluid exposure. |
P-13
|
|
| Julia Hollingsworth1; Carl Virtanen2; Angela Lau3; Alexandra Kollara3; Lisa Allen4; Terry Colgan1; Valerie Dube4; Barry Rosen5; K. Joan Murphy5; Ellen Greenblatt6; Tomer Feigenberg5; Alicia Tone5; Theodore Brown3 1Mount Sinai Hospital, Toronto, ON, Canada; 2PMH Genomics Centre, Toronto, ON, Canada; 3Lunenfeld Tanenbaum Research Institute, Toronto, ON, Canada; 4Women's College Hospital, Toronto, ON, Canada; 5Princess Margaret Cancer Centre, Toronto, ON, Canada; 6Mount Sinai Hospital, Toronto, ON, Canada |
||
| Regulation of ovarian surface epithelium stem cells by transforming growth factor beta 1 is mediated by Ptgs2 activation and Brca1 repression |
P-15
|
|
| Lauren Carter1; Olga Collins2; Lisa Gamwell1; David Cook1; Curtis McCloskey1; Holly Dempster1; Barbara Vanderhyden2 1University of Ottawa, Ottawa, ON, Canada; 2Ottawa Hospital Research Institute, Ottawa, ON, Canada |
||
| LKB1 is a central mediator of cell survival during stress metabolism in dormant ovarian cancer |
P-17
|
|
| Adrian Buensuceso; Yudith Ramos Valdes; Gabriel DiMattia; Trevor Shepherd The University of Western Ontario, London, Ontario, Canada |
||
| Functional analysis of the cell adhesion molecule Nectin-4 in ovarian cancer tumor progression |
P-19
|
|
| Kristin Boylan; Petra Buchanan; Dip Shukla; Cody Bruggemeyer; Kelly Braumberger; Amy Skubitz University of Minnesota, Minneapolis, MN, United States |
||
| Androgen receptor dependence for spontaneous juvenile-onset granulosa cell tumour initiation in a mouse model |
P-21
|
|
| Kerri Smith; Elizabeth Chia; Ann Dorward Memorial University of Newfoundland, St. John's, NL, Canada |
||
| Mechanisms driving tumorigenesis and histotype differentiation of high-grade serous ovarian cancer in Stk11/Pten-deleted mouse ovarian surface epithelium |
P-23
|
|
| Julienne Brock1; Timothy DeKoninck2; Jose Teixeira3 1College of Natural Science, Department of Physiology, Michigan State University, Grand Rapids, MI, United States; 2College of Human Medicine, Michigan State University, East Lansing, MI, United States; 3College of Human Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Michigan S, Grand Rapids, MI, United States |
||
| Global analysis of whole exome sequencing data from BRCA1/BRCA2 mutation carrier French Canadian women with ovarian cancer |
P-25
|
|
| Wejdan Alenezi1; Suzanna L. Arcand2; Dunarel Badescu3; Timothee Revil3; Anne-Marie Mes-Masso4; Diane Provencher4; Ioannis Ragoussis3; Patricia N. Tonin5 1Department of Human Genetics, McGill University, Montreal, QC, Canada; 2Cancer Research Program, The Research Institute of McGill University Health Centre, Montreal, QC, Canada; 3McGill University and Génome Québec Innovation Centre; Department of Human Genetics, McGill University, Montreal, QC, Canada; 4Centre de recherche du Centre hospitalier de l'Université de Montréal et Institut du cancer de Montreal, Montreal, QC, Canada; 5Departments of Human Genetics and Medicine, McGill University; Cancer Research Program, The Research, Montreal, QC, Canada |
||
| Micro-dissected ovarian tumors on-chip and protein biomarkers to predict carboplatin response of epithelial ovarian cancer |
P-27
|
|
| Euridice Carmona1; Benjamin Péant1; Mélina Astolfi2; Abdul Lateef1; Jennifer Kendall-Dupont1; Liliane Meunier1; Diane Provencher1; Thomas Gervais2; Anne-Marie Mes-Masson1 1Institut du cancer de Montréal, CRCHUM, Montreal, QC, Canada; 2Institut de génie biomédical, École Polytechnique, Montreal, QC, Canada |
||
| Diagnostic markers for patients with ovarian granulosa cell tumors; comparative analysis of CA125, HE4, Inhibin B and AMH |
P-29
|
|
| Ulla-Maija Haltia1; Marianne Hallamaa2; Johanna Tapper1; Johanna Hynninen2; Henrik Alfthan3; Olli Ritvos4; Markku Heikinheimo5; Leila Unkila-Kallio1; Antti Perheentupa2; Anniina Färkkilä1 1University of Helsinki, Department of Obstetrics and Gynecology and Helsinki University Central Hospital, Helsinki, Finland, Finland; 2University of Turku, Department of Obstetrics and Gynecology and Turku University Hospital, Turku, Finland, Finland; 3University of Helsinki, HUSLAB and Helsinki University Central Hospital, Helsinki, Finland; 4University of Helsinki, Finland; 5University of Helsinki, Children´s Hospital and Helsinki University Central Hospital, Helsinki, Finland |
||
| Analysis of genetic abnormalities involved in the development of ovarian tumors |
P-31
|
|
| Hanna Engqvist1; Elisabeth Werner Rönnerman1; Toshima Parris1; Elin Söderberg1; Jana Biermann1; Karin Sundfeldt1; Aniko Kovacs2; Per Karlsson1; Khalil Helou1 1Clinical Sciences/University of Gothenburg, Gothenburg, Vastra Gotaland, Sweden; 2Clinical Pathology and Genetics/University of Gothenburg, Vastra Gotaland, Sweden |
||
| Assessment of Pan-Canadian platform for known/proposed ovarian cancer susceptibility genes |
P-33
|
|
| Suzanna L. Arcand1; Dunarel Badescu2; Timothée Revil2; Pierre Bérubé3; Ioannis Ragoussis2; Patricia N. Tonin4 1Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC, Canada; 2McGill University and Génome Québec Innovation Centre; Department of Human Genetics, McGill University, Montreal, QC, Canada; 3McGill University and Génome Québec Innovation Centre, Montreal, QC, Canada; 4Departments of Human Genetics and Medicine, McGill University; Cancer Research Program, The Research, Montreal, QC, Canada |
||
| Relationship between genotype and clinical phenotype in French Canadian BRCA1-2 mutated women with ovarian cancer (FC-BMOC) |
P-35
|
|
| Diane Provencher1; Olivier Charrette2; Gilles Bleau2; Zaki El Haffaf3; Kurosh Rahimi1; Serge Nolet3; Patricia Tonin4 1CHUM - Notre-Dame Hospital, Montreal, QC, Canada; 2Université de Montréal, Montreal, QC, Canada; 3CRCHUM, Montreal, QC, Canada; 4McGill University, Montreal, QC, Canada |
||
| 17Beta-estradiol sensitizes ovarian surface epithelium to transformation by suppressing Dab2 expression |
P-37
|
|
| Nhung Vuong; Barbara Vanderhyden University of Ottawa, Ottawa, ON, Canada |
||
| Therapeutic relevance of Ran GTPase in epithelial ovarian cancer |
P-39
|
|
| Zied Boudhraa; Guergana Tchakarska; Estelle Schmitt; Kossay Zaoui; Euridice Carmona; Anne-Marie Mes-Masson CRCHUM, Montreal, QC, Canada |
||
| Interaction between the Notch and TGFbeta; signaling pathways in epithelial ovarian cancer cells |
P-41
|
|
| Jiesi Zhou; Abul Azad; Saket Jain; Xia Xu; HaiChuan Yu; Zhihua Xu; Roseline Godbout; YangXin Fu University of Alberta, Edmonton, AB, Canada |
||
| Development of in vitro disease models to study inactivating mutations of SWI/SNF protein complexes in aggressive dedifferentiated gynecological carcinomas |
P-43
|
|
| Mackenzie Coatham1; Xiaodong Li1; Bo Meng1; Martin Kobel2; Cheng-Han Lee1; Lynne-Marie Postovit1 1University of Alberta, Edmonton, AB, Canada; 2University of Calgary, Calgary, AB, Canada |
||
| Ventricular Zone Expressed Pleckstrin Homology Domain Homolog 1 (VEPH1) modulation of androgen signaling in ovarian cancer cells |
P-45
|
|
| Premalatha Shathasivam; Alexandra Kollara; Theodore Brown LTRI, Mount Sinai Hospital, Toronto, ON, Canada |
||
| Sphingosine-1-phosphate (S1P) promote ovarian cancer proliferation by disrupting Hippo signaling |
P-47
|
|
| Qianlan Fan University of British Columbia, Vancouver, BC, Canada |
||
| The role of ADAM10 and ADAM17 in ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer |
P-49
|
|
| Petra Buchanan; Kristin Boylan; Bruce Walcheck; Amy Skubitz UMN, Minneapolis, MN, United States |
||
| Mesothelial-tumor cell interactions for the formation of ovarian cancer multicellular spheroids |
P-51
|
|
| Clara Major Legault; Isabelle Matte; Claude Laplante; Perrine Garde-Granger; Paul Bessette; Alain Piché Université de Sherbrooke, Sherbrooke, QC, Canada |
||
| The regulation of ovarian cancer cell dormancy by the DREAM complex |
P-53
|
|
| Piru Perampalam1; James MacDonald2; Yudith Ramos2; Gabe DiMattia2; Fred Dick2 1UWO/London Regional Cancer Program, London, ON, Canada; 2UWO/London Regional Cancer Program, London, ON, Canada |
||
| Investigation of solute carrier Slc25a53 as a candidate ovarian tumour suppressor gene |
P-55
|
|
| Emily Cruickshank; Elizabeth Chia; Ann Dorward Memorial University of Newfoundland, St. John's, NL, Canada |
||
| Biology and tumorigenic capacity of self-assembled multicellular structures derived from serous ovarian cancer cells |
P-57
|
|
| Alicia A Goyeneche1; Juan M Valdez2; Rekha Srinivasan2; Zu-Hua Gao1; Carlos M Telleria1 1Department of Pathology, Faculty of Medicine, McGill University, Montreal, QC, Canada; 2Division of Basic Biomedical Sciences, Sanford School of Medicine of The University of South Dakota, Vermillion, SD, United States |
||
| 14:30 - 17:00 | Symposium II-Innovations in Experimental Model Systems Moderators: Theodore Brown, PhD, Lunenfeld-Tanenbaum Research Insitute and University of Toronto, Toronto, ON, Canada Blaise Clarke, MD, University of Toronto, Toronto, ON, Canada Coffee Station Available in Ballroom Foyer from 15:30-16:30 |
|
| 14:30 | Staring down the tube at the origins of ovarian cancer: impact on model systems |
SY-02.01
|
| Ron Drapkin Tenured Associate Professor; Director of Penn Ovarian Cancer Research Center; Director of Gynecology, Philadelphia, PA, United States |
||
| 15:30 | Gambling with biomarkers or going with the flow - patient derived models for personalized medicine |
SY-02.02
|
| Anne-Marie Mes-Masson Institut du cancer de Montréal, Montreal, QC, Canada |
||
| 16:00 | Ovarian cancer spheroids as an experimental model system for interrogating tumour dormancy |
SY-02.03
|
| Trevor Shepherd London Regional Cancer Program; Lawson Health Research Institute; Schulich School of Medicine & Dentistry, London, ON, Canada |
||
| 16:30 | Exploration SWI/SNF-PI3-kinase pathway crosstalk identifies new vulnerabilities in ARID1A-deficient ovarian tumors |
SY-02.04
|
| Jeanne Holladay; Ronald Chandler Michigan State University, Grand Rapids, MI, United States |
||
| 16:45 | The active sodium-glucose symporter SGLT2 is protective against cancer death, primary tumor growth, and metastatic secondary disease in an orthotopic mouse model of epithelial ovarian cancer |
SY-02.05
|
| Lisa Kellenberger; Jim Petrik University of Guelph, Guelph, ON, Canada |
||
| 17:00 - 17:30 | OCC Wine and Cheese Reception | |
| 17:30 - 18:30 | Special Performance by Jenny Allen "I got sick, then I got better" | |
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.